On October 11, we had the pleasure of opening the doors of our R&D Institute in Paris-Saclay for the first Partnering Day, an event dedicated to open discussion and collaboration on the latest innovations in the pharmaceutical sector. It was an opportunity to forge closer ties between industry players, share innovative ideas, and explore the challenges and opportunities shaping the future of healthcare.
An innovation-driven event
For our first Partnering Day, we welcomed around a hundred healthcare experts from pharmaceutical and biotech companies, as well as academics.
In her opening address, Chloé Leprêtre, Head of Global R&D Search and Evaluation, emphasized the significance of the occasion: “At Servier, we firmly believe that collaboration is the key to overcoming pharmaceutical innovation challenges of the future. This event is a special opportunity to share innovative ideas, expedite scientific research, and explore new avenues for the development of innovative therapies to benefit patients”
Inspiring presentations and round tables
The morning featured presentations from Servier R&D and a round-table discussion with experts involved throughout the partnership chain. Discussions covered a wide range of topics, including R&D strategy, new healthcare technologies (AI in particular), and the importance of sustainable partnerships to bring innovative therapeutic projects to fruition. Participants shared their experiences and visions, thereby enhancing the debate on best practices and future innovations.
Networking opportunities
Partnering Day also provided a wealth of networking opportunities. Partners were able to interact informally, make new contacts, and explore new paths of collaboration. Such interactions are essential for building a dynamic ecosystem in which innovation can flourish.
The day was also an opportunity for participants to learn more about Spartners by Servier & BioLabs, the start-up incubator housed in our R&D center.
Ranked as one of the eight clusters for innovation worldwide, along with Silicon Valley, Beijing, Boston and Silicon Wadi in Israel, Paris-Saclay has top-tier international influence. The site is home to key names in research as well as international companies, start-ups and renowned universities such as Paris-Saclay University, the first French university
Innovation to serve patient needs
At Servier, we understand the importance of open innovation. We consider it presents three main advantages—accelerate the speed of research, offer each project an optimal environment in which to thrive, and collaborate with the best partners for each project.
We believe in fostering synergy between shared expertise and harnessing the interdependence of our knowledge and savoir faire.
Partner of choice
Our partnership strategy centers around a single objective to ramp up the speed with which we develop treatments that significantly improve patients’ quality of life. We take a people-oriented approach to our partnerships, and we focus on creating win-win situations by pooling our expertise. We are keen to invest in innovation that benefits patients in the future.
70
Over 70 strategic alliances and research collaborations currently active
Scientific innovation by supporting biotechs and start-ups
At Servier, we firmly believe that an open approach is the best way to develop innovative therapeutic solutions that meet patients’ needs. That’s why we’re stepping up our initiatives with biotech companies with the sole aim of stimulating scientific innovation.
Each year, we support start-ups to achieve therapeutic progress through several programs:
In Saclay, Spartners by Servier & BioLabs, the start-up incubator for therapeutic innovation
Spartners by Servier & BioLabs, the start-up incubator at the Servier Research and Development Institute is unique in France. This new synergy between the momentum of young, future-facing companies and Servier’s pharmaceutical knowledge therefore creates unique conditions that will accelerate therapeutic research.
Operated by BioLabs, the leader in shared laboratories, Spartners by Servier & BioLabs is designed to accommodate around 15 start-ups, or over 100 scientists, in a 1,850 sqm building.